Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich’s Ataxia

 Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich’s Ataxia

Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich’s Ataxia

Shots:

  • Regenxbio to receive up front, development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio’s NAV AAV9 vector to develop & commercialize gene therapies for Friedreich’s ataxia
  • The focus of the agreement is to strengthen Regenxbio’s intellectual property portfolio and the potential of NAV AAV9 to treat systemic and CNS manifestations of movement disorders
  • Regenxbio’s NAV technology platform is an AAV gene delivery platform consisting of 100+ AAV vectors including AAV7, AAV8, AAV9 and AAVrh10 applicable for multiple therapeutic areas

Click here to­ read full press release/ article | Ref: Regenxbio | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post